Humanum CYP2C19 Gene Polymorphism

Cyp2c19 est unus de momenti medicamento metabolizing enzymes in CYP450 familia. Multi endogenous subiecta et circiter II% de orci medicinae sunt metabolized per CYP2C19, ut ad metabolismi antiplet aggregatio inhibitors (sicut clopidogrel), Pulkvulsants, etc. CYP2C19 Gene Polymorphisms etiam in Hetabolizing facultatem Related Medicamenta. These point mutations of *2 (rs4244285) and *3 (rs4986893) cause the loss of the enzyme activity encoded by the CYP2C19 gene and the weakness of metabolic substrate ability, and increase the blood concentration, so as to cause adverse drug reactions related to Sanguis concentration. * XVII (Rs12248560) posset auget enzyme operatio endoded per CYP2C19 gene, productio activae metabolitarum et augendae platelet aggregationem inhibitionis et augendae sanguinem periculum. Nam populus cum tardus metabolismus of medicinae, taking normalis doses diu erit causa gravis toxicus et latus effectus: maxime iecoris damnum, hematopoietic ratio dampnum, centralis nervosi damnum, etc., quod potest ad mortem in gravi casibus. Secundum singula differentias in correspondentes medicamento metabolismus, quod plerumque dividitur in quattuor phenotypes, nimirum ultra-ieiunium metabolismi (um, * XVII / XVII, * I / XVII), * I * I / I / * ), Media metabolismus (im, * I / II, * I / III), tardus metabolism (PM * II / II, * II / III, * III / III).